Diagnostic Breakthroughs for Neurodegenerative Diseases

1.1 Scope of Research

1.2 Research Methodology

1.2 Research Methodology (continued)

1.3 Key Findings

2.1 Overview of Neurodegenerative Diseases

2.2 Neurodegenerative Disease Diagnostics – Segmentation

2.3 Biomarker-based Diagnostics: Overview

2.3.1 Key Biomarkers for Neurodiagnostics

2.3.2 Emerging Biomarker Diagnostics for MCI, AD, TBI, PD and Dementia

2.3.3 Emerging Biomarker Diagnostics for ALS, FTD, TBI and AD

2.4 Neuroimaging Technologies: Overview

2.4.1 Neuroimaging Technologies

2.4.2 Neuroimaging Technologies

2.4.3 Neuroimaging Technologies

2.4.4 Neuroimaging Technologies: Innovation Ecosystems

2.5 Neuroinformatics: Overview

2.6 Neuroinformatics: Innovation Ecosystems

3.1 Venture Investment Scenario for Neurobiomarkers

3.2 Public Funding Landscape for Neurobiomarker Projects

3.3 Summary of Key Public Funding Trends for Neurobiomarker Projects

4.1 Key Technological Drivers and Challenges Across Neurodiagnostic Markets

4.1.1 Key Technologies Driving the Growth of Global Neurodiagnostic Markets

4.1.2 Technological Challenges Across the Neurodiagnostic Sector

4.2 Overview of Key Market Drivers and Challenges Across the Neurodiagnostic Sector

4.2.1 Key Market Drivers Fueling the Growth of the Global Neurodiagnostic Sector

4.2.2 Key Market Challenges Impeding the Advancements of Neurodiagnostics

4.3 Clinical Trials Analysis for Neuroimaging Markets in the US

4.4 Adoption Scenario for Biomarker Diagnostics

4.5 Adoption Scenario for Neuroimaging Techniques

4.6 Adoption Scenario for Neuroinformatic Tools

5.1 Overview of the Collaborative Landscape Across Neurodiagnostic Markets

5.2 Product Development Partnerships – Diagnostics

5.3 Product Development Partnerships – Companion Diagnostics

5.4 Licensing and Research Collaborations – Neurodiagnostics

5.5 Research Consortia Across Global Neurodiagnostic Markets

5.6 Emerging Technologies in Neurodiagnostics

5.7 Conclusions

6.1 Patent Search Scope

6.2 Patents for Neurodegenerative Diseases – Timeline Overview

6.3 Global Patent Spread by Assignees

6.4 Global Patent Spread by Patent Offices

7.1 Key Contacts

7.2 Appendix I

7.2 Appendix I

7.3 Appendix II

Legal Disclaimer

8.1 The Frost & Sullivan Story

8.2 Value Proposition: Future of Your Company & Career

8.3 Global Perspective

8.4 Industry Convergence

8.5 360º Research Perspective

8.6 Implementation Excellence

8.7 Our Blue Ocean Strategy